A new drug was so successful in its first trial that it is now being considered the new standard therapy for type 2 diabetes.
The drug that is called semaglutide, is manufactured by Novo Nordisk.
“We are excited about the potential of semaglutide to set a new standard for treatment of type 2 diabetes,” Novo Nordisk said.
“While we project that Lilly will retain its leadership position in the once-weekly segment, Novo has made headway with its oral formulation that could potentially shift the market dynamics in its favor over the longer term,” Barclays analysts said. source